Chardan Capital Downgrades Passage Bio to Neutral, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 86.9%

Neg 86.9% Neu 0% Pos 0%

Chardan Capital analyst Janani Sundararajan downgrades Passage Bio (NASDAQ:PASG) from Buy to Neutral and lowers the price target from $21 to $7.